Glyphic Biotechnologies

Next Generation Protein Sequencing

Berkeley, United States · Founded 2021 · $44.1M raised

Employees
11–50
Founded
2021
Business Model
B2B
Total Funding
$44.1M
Last Round
$2.9M Series ASep 2025
Rounds
7

Totals include recorded grants and other qualifying funding, not just equity. What counts toward funding.

Indexed holds 7 funding rounds and 2 investors for this company. The full record is or through the API.

About

Founded in 2021 and headquartered in Berkeley, California, Glyphic Biotechnologies exists to fundamentally rewrite the rules of proteomics. The company is developing Protein Sequencing by Expansion (ProSE™), the first truly de novo high-throughput proteome sequencing technology capable of discriminating all 20 amino acids and post-translational modifications with single-molecule sensitivity. Glyphic's platform leverages spatial expansion of amino acids to enable massively parallel proteome sequencing, unlocking critical first-in-class therapies and deeper insights into biology.

Summary

Glyphic Biotechnologies is a Biotech company based in Berkeley, United States, founded in 2021. It has raised $44.1M in total across 7 rounds, most recently a $2.9M Series A round in Sep 2025. Investors include OMX Ventures and Osage University Partners.

Tech & App Stack

20 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding History

Series ASeries A ExtendedSep 2025
$2.9M

Sign up to see all 7 events

Funding: Seed through Series A. Amounts, valuations, and investors where available.

Investors

Similar Companies

PacBioIPO

Developer and manufacturer of high-accuracy long-read DNA sequencing systems and consumables for ...

USA, United States501–1000Biotech, Genomics
ConvertibleTotal funding$1.2BFeb 2021
Element Biosciences

Life science company democratizing access to advanced DNA sequencing tools with high-quality, aff...

San Diego, United States201–500Biotech, Genomics
Series ETotal funding$853.3MJun 2026
LifeMine

Therapeutics company working in drug discovery and development using fungi with genomics approach...

Watertown, United States51–200Biotech, Drug Discovery
Venture RoundTotal funding$816.0MAug 2026
Tessera Therapeutics

Develops Gene Writing technology and non-viral delivery to create in vivo genetic medicines for m...

Somerville, United States201–500Biotech, Genomics
Corporate RoundTotal funding$730.0MDec 2025
Altos Labs

Altos Labs combines academic science and industry development to create medicines that restore ce...

San Francisco, United States501–1000Life Sciences, Biotech
Series ATotal funding$3.0BJan 2022
BridgeBioIPO

BridgeBio develops treatments for genetic conditions through autonomous condition-focused teams s...

San Francisco Bay Area, United States201–500Biotech, Healthcare
Growth EquityTotal funding$2.7BJul 2026

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

Glyphic Biotechnologies on Indexed.vc
<a href="https://indexed.vc/companies/glyphic-biotechnologies"><img src="https://indexed.vc/api/badge/company/glyphic-biotechnologies" alt="Glyphic Biotechnologies on Indexed.vc" width="260" height="76" /></a>